Indirect evidence suggests that amniotic fluid (AF) may play a role in the pathogenesis of in utero HIV-1 transmission. The purpose of this study was to evaluate the potential innate inhibitory role of AF on HIV replication, which may contribute to protection of the fetus against intrauterine transmission. AF was collected from term HIV-1-negative women undergoing scheduled cesarean section. The inhibitory effect of AF against HIV-1BA-L replication was tested in vitro with or without the addition of protease inhibitor cocktail (PIC) in PHA-stimulated PBMC cultures. Quantitative measurement of human neutrophil peptides 1-3 (HNP1-3) was performed on all AF samples, using an ELISA assay. AF exhibited a dose-dependent inhibitory activity against HIV-1BA-L replication, with all samples (n=12) reaching significant inhibitory effect using 50% AF. In vitro, this activity decreased over time, but was able to be sustained with the addition of PIC. The HNP1-3 concentration in AF samples (n=12) ranged from undetectable (<41 pg/ml, n=3) to >250,000 pg/ml with a median of 5,146 pg/ml. AF exhibited a significant and dose-dependent innate inhibitory activity against HIV-1 replication, which was present in all AF samples tested. This effect was prolonged in the presence of PIC, suggesting that the inhibitory factor was in the cell-free protein fraction. The HNP1-3 concentration in AF was in the subinhibitory range for HIV with no correlation between its concentration and the HIV-1 inhibitory activity. These data show the presence of a significant innate inhibitory activity against HIV in AF.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization and UNAIDS. Global summary of AIDS epidemic. 20092012 9 17www.who.int/hiv/data/2009_global_summary.png.
2.
BrysonYJ, LuzuriagaK, SullivanJL, WaraDW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med, 1992; 327:1246–1247.
3.
DevilleJ, BrysonY. Perinatal transmission of HIV: Recognition and treatment interventions. Curr Infect Dis Rep, 2001; 3:388–396.
4.
RevelloMG, GernaG. Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. J Clin Virol, 2004; 29:71–83.
5.
MundyDC, SchinaziRF, GerberAR, NahmiasAJ, RandallHW:Jr. Human immunodeficiency virus isolated from amniotic fluid. Lancet, 1987; 2:459–460.
6.
TessBH, RodriguesLC, NewellML, DunnDT, LagoTD. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. AIDS, 1998; 12:513–520.
7.
FazelyF, SharmaPL, FratazziCet al.Simian immunodeficiency virus infection via amniotic fluid: A model to study fetal immunopathogenesis and prophylaxis. J Acquir Immune Defic Syndr, 1993; 6:107–114.
8.
NielsenK, BoyerP, DillonMet al.Presence of human immunodeficiency virus (HIV) type 1 and HIV-1-specific antibodies in cervicovaginal secretions of infected mothers and in the gastric aspirates of their infants. J Infect Dis, 1996; 173:1001–1004.
9.
LewisDB, GernJE, HillHRet al.Newborn immunology: Relevance to the clinician. Curr Probl Pediatr Adolesc Health Care, 2006; 36:189–204.
10.
JaspanHB, RobinsonJE, AmedeeAM, Van DykeRB, GarryRF. Amniotic fluid has higher relative levels of lentivirus-specific antibodies than plasma and can contain neutralizing antibodies. J Clin Virol, 2004; 31:190–197.
11.
BowdlerNC, GalaskRP. Amniotic fluid, its relation to infections. Obstetric and Gynecologic Infectious Disease. PastorekJG. Raven Press: New York, 1994; 417–425.
12.
PacsaAS. Impairment of immunity during pregnancy and antiviral effect of amniotic fluid. Lancet, 1977; 1:330–331.
13.
AkinbiHT, NarendranV, PassAK, MarkartP, HoathSB. Host defense proteins in vernix caseosa and amniotic fluid. Am J Obstet Gynecol, 2004; 191:2090–2096.
14.
YoshioH, TollinM, GudmundssonGHet al.Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: Implications for newborn innate defense. Pediatr Res, 2003; 53:211–216.
15.
ChangTL, Vargas JJr, DelPortilloA, KlotmanME. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest, 2005; 115:765–773.
16.
van der StrateBW, BeljaarsL, MolemaG, HarmsenMC, MeijerDK. Antiviral activities of lactoferrin. Antiviral Res, 2001; 52:225–239.
17.
McNeelyTB, DealyM, DrippsDJ, OrensteinJM, EisenbergSP, WahlSM. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest, 1995; 96:456–464.
18.
Lee-HuangS, MaiorovV, HuangPLet al.Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry, 2005; 44:4648–4655.
19.
BergmanP, Walter-JallowL, BrolidenK, AgerberthB, SoderlundJ. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res, 2007; 5:410–415.
20.
HeinM, ValoreEV, HelmigRB, UldbjergN, GanzT. Antimicrobial factors in the cervical mucus plug. Am J Obstet Gynecol, 2002; 187:137–144.
EspinozaJ, ChaiworapongsaT, RomeroRet al.Antimicrobial peptides in amniotic fluid: Defensins, calprotectin and bacterial/permeability-increasing protein in patients with microbial invasion of the amniotic cavity, intra-amniotic inflammation, preterm labor and premature rupture of membranes. J Matern Fetal Neonatal Med, 2003; 13:2–21.
23.
KuhnL, TrabattoniD, KankasaCet al.Alpha-defensins in the prevention of HIV transmission among breastfed infants. J Acquir Immune Defic Syndr, 2005; 39:138–142.
24.
PanyutichAV, PanyutichEA, KrapivinVA, BaturevichEA, GanzT. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J Lab Clin Med, 1993; 122:202–207.
LevinsonP, KaulR, KimaniJet al.Levels of innate immune factors in genital fluids: Association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS, 2009; 23:309–317.
27.
ChangTL, KlotmanME. Defensins: Natural anti-HIV peptides. AIDS Rev, 2004; 6:161–168.
28.
ColeAM, ColeAL. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol, 2008; 59:27–34.
29.
VenkataramanN, ColeAL, SvobodaP, PohlJ, ColeAM. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol, 2005; 175:7560–7567.
30.
StiehmER, LambertJS, MofensonLMet al.Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis, 1999; 179:567–575.
31.
DickoverR, GarrattyE, YusimK, MillerC, KorberB, BrysonY. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol, 2006; 80:6525–6533.
32.
DickoverR, NielsenK, YusimK, KorberB, JinJ, BrysonY. Perinatal transmission of HIV-1 via amniotic fluid, vaginal secretions, blood: A molecular analysis. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005.
33.
HeinM, HelmigRB, SchonheyderHC, GanzT, UldbjergN. An in vitro study of antibacterial properties of the cervical mucus plug in pregnancy. Am J Obstet Gynecol, 2001; 185:586–592.
34.
MillerRK, PolliottiBM, LaughlinTet al.Role of the placenta in fetal HIV infection. Teratology, 2000; 61:391–394.
35.
HolloxEJ, BarberJC, BrookesAJ, ArmourJA. Defensins and the dynamic genome: What we can learn from structural variation at human chromosome band 8p23.1. Genome Res, 2008; 18:1686–1697.
36.
WangTT, NestelFP, BourdeauVet al.Cutting edge: 1,25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol, 2004; 173:2909–2912.
